SOLTI Archives

Mafalda Oliveira receives a CRIS Cancer Foundation award to conduct a clinical trial in patients with early-stage triple-negative breast cancer

On April 9, the CRIS Cancer Foundation held the 2026 “CRIS Science Day” featuring the III CRIS International Symposium, focused…

The PremiÈRe study positions elacestrant as a promising drug for the treatment of breast cancer in young women diagnosed during premenopause

The Phase 2 clinical trial PremiÈRe (SOLTI-2104) is the first to evaluate the oral drug elacestrant -either alone or combined…

A study led by SOLTI and VHIO facilitates nationwide access to genomic testing across Spain for patients with metastatic prostate cancer and redefines therapeutic strategy in more than half of cases

The HOPE Prostate (SOLTI-2102) study analyzed 208 samples (116 tissue and 92 liquid biopsies) from 146 patients with metastatic prostate…

DESTINY-Breast09: novel combination therapy demonstrates significantly improved outcomes as first line therapy in HER2+ metastatic breast cancer, pointing to a new standard of care for a broad population of patients

Results from interim analysis of the international, multicenter, randomized phase III DESTINY-Breast09 study show that the combination of trastuzumab dertuxtecan…

Patritumab deruxtecan reduces serious side effects in breast cancer patients compared to conventional chemotherapy while maintaining treatment efficacy

The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard…

POSITIVE results show that temporarily discontinuing endocrine therapy to attempt pregnancy after breast cancer does not increase the short-term risk of disease relapse

Published in The New England Journal of Medicine (1), first results of the international POSITIVE study co-authored by VHIO’s Cristina…